Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
David Wang(University of California, San Francisco), Jason Quiros(University of California, San Francisco), Kelly M. Mahuron(University of California, San Francisco), Chien-Chun Steven Pai(University of California, San Francisco), Valeria Ranzani(Istituto Nazionale Genetica Molecolare), Arabella Young(University of California, San Francisco), Stephanie Silveria(University of California, San Francisco), Tory Harwin(University of California, Berkeley), Arbi Abnousian(University of California, Berkeley), Massimiliano Pagani(University of Milan), Michael D. Rosenblum(University of California, San Francisco), Frédéric Van Gool(University of California, San Francisco), Lawrence Fong(University of California, San Francisco), Jeffrey A. Bluestone(University of California, San Francisco), Michel DuPage(University of California, San Francisco)
Cited by 308Open Access
Abstract
effector T cells that eliminate tumors. Moreover, abolishing EZH2 function in Tregs was mechanistically distinct from, more potent than, and less toxic than a generalized Treg depletion approach. This study reveals a strategy to target Tregs in cancer that mitigates autoimmunity by reprogramming their function in tumors to enhance anti-cancer immunity.
Related Papers
No related papers found
Powered by citation graph analysis